Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.65 |
| ▸ | CREBBP | Q92793 | 15/20 | 0.65 |
| ▸ | EP300 | Q09472 | 1/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20611723 | 0.83 | CREBBP (0.51) | BRD4CREBBPEP300EPHX2SIRT1 | |
| SCHEMBL17673137 | 0.82 | CREBBP (0.63) | BRD4CREBBPEP300 | |
| SCHEMBL17749826 | 0.82 | BRD4 (0.63) | BRD4CREBBPEP300 | |
| SCHEMBL19518213 | 0.82 | CREBBP (0.63) | BRD4CREBBPEP300 | |
| SCHEMBL19651828 | 0.80 | CREBBP (0.60) | BRD4CREBBPEP300 | |
| SCHEMBL4902318 | 0.79 | CREBBP (1.00) | BRD4CREBBPEP300 | |
| SCHEMBL17680234 | 0.79 | CREBBP (1.00) | BRD4CREBBPEP300 | |
| SCHEMBL17680584 | 0.79 | CREBBP (1.00) | BRD4CREBBPEP300 | |
| SCHEMBL22868112 | 0.76 | ACHE (0.46) | BRD4CREBBPEP300EPHX2 | |
| SCHEMBL15918985 | 0.75 | CREBBP (0.56) | BRD4CREBBPEP300EPHX2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3647311-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | BRD4 295/4885CREBBP 577/4885EP300 3151/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | BRD4 1/4885CREBBP 34/4885EP300 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.